Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewIt’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal Share XMerck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewhttps://pharmaphorum.com/news/merck-cos-keytruda-gets-new-colorectal-cancer-use-after-month-long-fda-review/
Merck & Co’s Keytruda approved for second “tumour agnostic” useMerck & Co’s Keytruda cancer immunotherapy has been approved by the FDA in another “tumour agnostic” use, in Share XMerck & Co’s Keytruda approved for second “tumour agnostic” usehttps://pharmaphorum.com/news/merck-cos-keytruda-approved-for-second-tumour-agnostic-use/
Merck & Co’s Keytruda fails in first line bladder cancerMerck & Co’s bid to become standard care in untreated bladder cancer has run into trouble after its Share XMerck & Co’s Keytruda fails in first line bladder cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-first-line-bladder-cancer/
ASCO 2020 round-up: Virtual conference still delivers the dramaASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping Share XASCO 2020 round-up: Virtual conference still delivers the dramahttps://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/
Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerMerck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, Share XMerck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/
Merck & Co squares up to Roche with Keytruda data in triple-negative breast cancerRoche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe Share XMerck & Co squares up to Roche with Keytruda data in triple-negative breast cancerhttps://pharmaphorum.com/news/mercks-squares-up-to-roche-with-keytruda-data-in-triple-negative-breast-cancer/
Merck builds case for six-week Keytruda dosing as FDA starts reviewMerck & Co’s checkpoint inhibitor Keytruda can be given half as often and still retain its efficacy, according Share XMerck builds case for six-week Keytruda dosing as FDA starts reviewhttps://pharmaphorum.com/news/merck-builds-case-for-six-week-keytruda-dosing-as-fda-starts-review/
FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ useMerck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use Share XFDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ usehttps://pharmaphorum.com/news/fda-reviews-merck-cos-keytruda-in-new-tumour-agnostic-use/
FDA to quickly review Roche’s chemo-free lung cancer regimenRoche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the Share XFDA to quickly review Roche’s chemo-free lung cancer regimenhttps://pharmaphorum.com/news/roche-closing-in-on-chemo-free-first-line-nsclc-regimen/
